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Abstract 
Review on t(3;11)(p11;p15), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Acute myeloid leukemia (AML) 
Epidemiology 
Two cases to date. In the first case, a 57-year-old 
female was initially diagnosed with a breast 
adenocarcinoma and she developed therapy-related 
AML-M4 fourteen years later (Lisboa et al., 2013). 
In the second case, a 19-year-old white male was 
diagnosed with de novo AML-M4 (Walker et al., 
2013). 
Prognosis 
The first patient was treated with chemotherapy 
(cytarabine, daunorubicin, and cyclosporin) and a 
complete response was achieved. The patient 
showed evidence of relapse ten months later and died 
within five months after relapse (Lisboa et al., 2013). 
The second patient had complete remission (CR) 
after induction treatment with cytarabine and 
daunorubicin.  The post-CR therapy included high-
dose cytarabine, cytoxan, and etoposide.  The patient 
had a disease-free survival of 92+ months and an 
overall survival of 92.9+ months (Walker et al., 
2013). 
Genes involved and 
proteins 
NUP98 (nucleoporin 98) 
Location 
11p15 
Protein 
A 98 kDa nucleoporin.  It is a component of the 
nuclear pore complexes (NPCs) and participates in 
many cellular processes, including nuclear import, 
nuclear export, mitotic progression, and regulation 
of gene expression (Gough et al., 2011).  NUP98 
protein contains N-terminal Gly-Leu-Phe-Gly 
(GLGF) repeat domains and a C-terminal RNA 
binding domain.  Translocations between this gene 
and many other partner genes have been observed in 
leukemias. Rearrangements typically result in fusion 
proteins with the N-terminal GLGF domain of this 
gene to the C-terminus of the partner gene and they 
seem to be associated with poor prognosis (Struski 
et al., 2017; Kearney, L 2002). 
POU1F1 (POU class 1 homeobox 1) 
Location 
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3p11 
Protein 
POU1F1, also known as PIT1, is a member of the 
POU family of transcription factors.  It regulates 
expression of several genes involved in pituitary 
development and hormone expression (Ingraham et 
al., 1998) and also plays a role in cell proliferation 
and differentiation (Costoya et al., 1998; Pellegrini 
et al., 2006).  Deregulation of POU1F1 is implicated 
in pituitary adenoma, combined pituitary hormone 
deficiency, breast carcinoma, and acute myeloid 
leukemia (Franc et al., 2014; Gao et al., 2016).  
POU1F1 protein contains an N-terminal 
transactivation domain and a C-terminal DNA 
binding domain including a homeodomain (Franc et 
al., 2014). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Description: 5' NUP98 - 3' POU1F1 was produced in 
the case reported by Lisboa et al. in 2013.  The 
breakpoints were 7490 bp downstream of NUP98 
exon 11 and 129 bp downstream of the start of 
POU1F1 exon 4 (Figure A).  The POU1F1 exon 4 
was not included in the mature NUP98/POU1F1 
message RNA (Lisboa et al., 2013). 
 
 
 Fusion protein 
 
Schematic representation of the NUP98-POU1F1 fusion protein (Modified from Lisboa et el., 2013). 
Description 
The NUP98/POU1F1 fusion protein contains the 
GLFG repeats of NUP98 and the homeodomian of 
POU1F1 (Figure B). 
Oncogenesis 
It is expected that the expression of NUP98/POU1F1 
fusion gene is under the control of NUP98 promoter, 
leading to POU1F1 overexpressioin which results in 
increased proliferation of leukemia cells. It is 
hypothesized that the FLT3-ITD mutation 
collaborates with NUP98/POU1F1 in malignant 
transformation (Lisboa et el., 2013). 
References 
Costoya JA, García-Barros M, Gallego R, Señarís R, Arce 
VM, Devesa J. Correlation of Pit-1 gene expression and Pit-
1 content with proliferation and differentiation in human 
myeloid leukemic cells. Exp Cell Res. 1998 Nov 
25;245(1):132-6 
Franc JL, Becquet D, Franè_ois-Bellan AM.. POU1F1 (POU 
class 1 homeobox 1) Atlas Genet Cytogenet Oncol 
Haematol. 2014;18(10):728-730. 
Gao Z, Xue K, Zhang L, Wei M. Over-Expression of POU 
Class 1 Homeobox 1 Transcription Factor (Pit-1) Predicts 
Poor Prognosis for Breast Cancer Patients Med Sci Monit  
2016 Oct 31;22:4121-4125 
 
Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and 
hematopoietic malignancies: common themes and new 
biologic insights Blood  2011 Dec 8;118(24):6247-57 
Ingraham HA, Chen RP, Mangalam HJ, Elsholtz HP, Flynn 
SE, Lin CR, Simmons DM,  Swanson L, Rosenfeld MG. A 
tissue-specific transcription factor containing a 
homeodomain specifies a pituitary phenotype Cell  1988 
Nov 4;55(3):519-29 
 
Franc JL, Becquet D, François-Bellan AM. Kearney, L. 
POU1F1 (POU class 1 homeobox 1) NUP98 (nucleoporin 
98 kDa) Atlas Genet Cytogenet Oncol Haematol. 
2014;18(10):728-730. 
Kearney, L. NUP98 (nucleoporin 98 kDa) Atlas Genet 
Cytogenet Oncol Haematol. 2002;6(3):193-196. 
Lisboa S, Cerveira N, Bizarro S, Correia C, Vieira J, Torres 
L, Mariz JM, Teixeira MR. POU1F1 is a novel fusion partner 
of NUP98 in acute myeloid leukemia  with t(3;11)(p11;p15) 
Mol Cancer  2013 Jan 18;12:5 
Pellegrini I, Roche C, Quentien MH, Ferrand M, Gunz G, 
Thirion S, Bagnis C, Enjalbert A, Franc JL. Involvement of 
the pituitary-specific transcription factor pit-1 in 
somatolactotrope cell growth and death: an approach using 
dominant-negative pit-1 mutants Mol Endocrinol  2006 
Dec;20(12):3212-27 
Struski S, Lagarde S, Bories P, Puiseux C, Prade N, 
Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-
t(3;11)(p11;p15) NUP98/POU1F1  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(12) 509 
 
Pochitaloff M, Roche-Lestienne C, Barin C, Penther D,  
Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, 
Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, 
Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse 
E. NUP98 is rearranged in 3 8% of pediatric AML forming a 
clinical and  molecular homogenous group with a poor 
prognosis  Leukemia 
Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, 
Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD; Alliance 
for Clinical Trials in Oncology. New recurrent balanced 
translocations in acute myeloid leukemia and 
myelodysplastic syndromes: cancer and leukemia group B 
8461 Genes Chromosomes Cancer  2013 Apr;52(4):385-
401 
This article should be referenced as such: 
Zhong Y, Piazza M, Shetty S. t(3;11)(p11;p15) 
NUP98/POU1F1. Atlas Genet Cytogenet Oncol 
Haematol. 2018; 22(12):507-509. 
